Thalidomide treatment for immunoglobulin D multiple myeloma in a patient on chronic hemodialysis.
A 64-year-old Japanese man suffering from IgD lambda myeloma and renal failure requiring chronic hemodialysis was treated with thalidomide. Serum IgD concentration was 4,050 mg/dl and myeloma cells constituted 95.6% of nucleated cells in bone marrow at the start of treatment. These parameters improved markedly to 1,590 mg/dl and 22.0%, respectively, in the 4 months immediately prior to his death due to pneumonia. Thalidomide caused peripheral neuropathy and constipation at a dose of 100 mg daily in the first week of treatment, but adverse effects resolved upon dose reduction. Thalidomide represents a valid therapeutic option for some myeloma patients receiving hemodialysis.
Hayashi
Tatsuyuki
T
Division of Internal Medicine, Tokyo Metropolitan Police Hospital, Tokyo.
Yamaguchi
Izumi
I
Saitoh
Hiroki
H
Takagi
Masao
M
Nonaka
Yasunobu
Y
Nomura
Takeo
T
D006801:Humans; D007072:Immunoglobulin D / Q000097:blood*; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006435:Renal Dialysis; D013792:Thalidomide / Q000009:adverse effects / Q000627:therapeutic use*
D007072:Immunoglobulin D; D007166:Immunosuppressive Agents; D013792:Thalidomide